Medtronic (NYSE:MDT) said today that the FDA granted an investigational device exemption for a clinical trial of its Visualase ablation device in treating temporal lobe epilepsy. Fridley, Minn.-based Medtronic put $105 million on the table for Houston-based Visualase back in 2014, including $70 million in up-front cash and another $35 million in milestones. Medtronic had […]